MBL77 OPTIONS

Not all sufferers with CLL call for therapy. Even with all current innovations, the iwCLL still recommends watchful observation for sufferers with asymptomatic disease.86 This suggestion relies on at the very least two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).10